ArticleMolecular diversity2026
DeepPepQSAR: all-in-one for comprehensively exploiting the vast molecular diversity space of bioactive peptide universe.
Article in Molecular diversity, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
Peptide quantitative structure-activity relationship (PepQSAR) has attracted much attention in the bio- and cheminformatics communities as a well-established computational peptidology strategy to statistically correlate the sequence/structure and activity/function of bioactive peptides (BAPs). In this study, a new concept termed DeepPepQSAR that integrates deep learning into traditional PepQSAR is proposed to quantitatively model, predict, and interpret the BAP universe in an all-in-one manner, that is, massive BAP samples with diverse activity types (i.e. antimicrobial, antiviral, hemolytic, anticancer, antigen, ACE-inhibitory, antioxidant, domain-binding, etc.) are merged into a single all-in-one DeepPepQSAR framework for artificial intelligence (AI)-driven big-data BAP discovery. A novel PepImage map is described to graphically represent both the sequence features of length-varying peptides and the activity types tested for these peptides, which is then fed into a dual-path, single-/multiple-channel convolutional neural network (CNN) for training, developing, and validating DeepPepQSAR regression models. We also practice the CNN-based DeepPepQSAR methodology on extrapolative navigation across a large-scale molecular diversity space covering billions of peptidic fragment candidates generated systematically from various food-derived proteins (FDPs) for AI-driven antimicrobial food peptide (AMFP) and antihypertensive food peptide (AHFP) discovery. Consequently, 14 AMFP peptides and 10 AHFP peptides are determined to have good antibacterial and ACE-inhibitory profiles, in which 4 and 2 peptides exhibit high potencies, respectively.
Indexed as
Identifiers
42435194What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.